ArticleJAMA2016
Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
Article in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder.Journal of child and adolescent psychopharmacology · 2020Trial
- Psychotropic Medication Use by Children with Autism Served in Publicly Funded Mental Health Settings.Journal of developmental and behavioral pediatrics : JDBPTrial
- Risk factors and pattern of weight gain in youths using antipsychotic drugs.European child & adolescent psychiatry · 2021Article
- Parent and Teacher Training Increases Medication Adherence for Primary School Children With Attention-Deficit/Hyperactivity Disorder.Frontiers in pediatrics · 2020Article
- Effects of Methylphenidate on Cognitive Function in Adults with Traumatic Brain Injury: A Meta-Analysis.Brain sciences · 2019Article
- Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.Pharmacology, biochemistry, and behavior · 2019Article
- Selectivity of probes for PET imaging of dopamine D3 receptors.Neuroscience letters · 2019Review
- ADHD Medication and Substance-Related Problems.The American journal of psychiatry · 2017Article
- Racial and Ethnic Differences in ADHD Treatment Quality Among Medicaid-Enrolled Youth.Pediatrics · 2017Article
- Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.Evidence-based mental health · 2016Article
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical questionIs treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)? BOTTOM LINE: Methylphenidate is associated with improvement in ADHD symptoms, general behavior, and quality of life; however, due to the very low quality of the evidence, the magnitude of the associated improvement is uncertain. Methylphenidate was associated with an increased risk of nonserious adverse events. There are too few data to assess the association with serious adverse events.
Indexed as
Identifiers
27163989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.